Replies to post #426914 on Amarin Corp Plc (AMRN)

[couldbebetter]

Southpacific, I agree AMRN should find a way to get
a retraction of Nissan's biased JAMA article. If that is
possible, then why has it not yet been done? The annual
potential sales amount for Vazkepa I would use something
closer to future reality. My opinion is Vazkepa may end up
selling at around $80 a month or $960 a year. Obviously,
it will have to sold at a price to allow a profit. I would think
that at a minimum, peak sales would be over $2 billion a year
with the right Eurocentric BP owner in place. In theory, that
would potentially make AMRN's value to a BP in Europe
around $9 billion or $20 a share. (That is without any new
patents for new formulations and new indications.)